Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE: Capecitabine in Elderly Stage III Colon Cancer
NCT02978612Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Jun 2016
- Primary completion
- Nov 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine in colon cancer, sponsored by Oslo University Hospital. Primary endpoint: Functional decline in instrumental activities of daily living and/or activities of daily living at 1 year. Started Jun 2016; status: completed.
02
Drugs
capecitabine
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT02978612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978612.